Historically, biguanides and sulfonylureas were the most heavily prescribed T2D drug classes. However, the DPP-IV inhibitors have recently overtaken sulfonylureas to become the second-most heavily prescribed drug class. Numerous branded agents jostle for position as second-line treatment options, including the DPP-IV inhibitors, the SGLT2inhibitors Jardiance, Invokana and Farxiga, the GLP-1 receptor agonists Victoza and Trulicity, and the insulins. Adding to the complexity of the market dynamics, the biosimilar insulin Basaglar is also picking up significant patient share.
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed type 2 diabetes patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed type 2 diabetes patients?
- What proportion of type 2 diabetes patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of type 2 diabetes patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated patients with type 2 diabetes?
Key analysis provided:
- Brand usage across longitudinal patient sample
- Newly diagnosed patient analysis
- Treatment initiation and progression
- Line of therapy analysis
- Combination therapy analysis
- Source of business for recently treated patients
- Persistency and compliance analysis
- Product-level patient flow charts
Markets covered: United States
Primary research: Longitudinal patient-level claims data analysis